10x Genomics Tumbles 12% — When High Science Meets Low Growth

Genomics just saw its shares crater by 12% in a single session, a massive gut punch for the bulls of this biotech leader. Despite a solid Q4 earnings beat, the market is panicking after Cathie Wood’s ARK Invest—one of the company’s most vocal supporters—dumped over 473,000 shares. In this episode, we break down why the "growth" story is officially on life support as revenue guidance remains stagnant, even as the company sits on a $520 million cash pile. Is this a sign that institutional patience for hardware-heavy biotech is wearing thin, or is the market overreacting to a shift in the investor base? Tune in to find out if 10x Genomics is still a lab winner or a Wall Street warning.